A fully human antibody binding to human cytomegalovirus and its application
By developing high-affinity antibodies that bind human cytomegalovirus gB protein, the shortcomings in the treatment and prevention of HCMV in the prior art were solved, especially in fibroblast infection, and effective prevention and treatment of HCMV were achieved. .
Patent Information
- Application Number
- CN202410222972.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-02-28
AI Technical Summary
Existing anti-cytomegalovirus (HCMV) treatments and vaccines have shortcomings in prevention and treatment, especially in the early steps of virus entry into host cells, existing antibodies are ineffective against fibroblast infection and drug resistance issues are not fully resolved .
A high-affinity antibody or antigen-binding fragment thereof that binds human cytomegalovirus gB protein, including specific heavy and light chain variable region sequences, is developed for the preparation of prevention or treatment of HCMV-related diseases and is used for detection.
This antibody can efficiently bind the gB protein of HCMV, providing prevention and treatment effects on HCMV, especially in preventing fibroblast infection, and reducing the risk of drug resistance.
Smart Images

Figure CN118126162B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of antibody technology, and in particular to a fully human antibody binding to human cytomegalovirus and its application. Background Art
[0002] Of all the viruses known to infect humans, human cytomegalovirus (HCMV) has the largest genome (~235kb of double-stranded DNA) and encodes more than 250 open reading frames. Once infected with HCMV, it will persist for life. After the initial infection, HCMV will remain latent for a long time, and individuals with normal immune function will show asymptomatic infection, but in immunosuppressed people or those receiving organ or hematopoietic stem cell transplants, HCMV reactivation will lead to high morbidity and mortality. In addition, HCMV, which can cross the placental barrier and infect the fetus during pregnancy, is also extremely threatening and can cause congenital birth defects, including brain damage, hearing loss, learning disabilities, heart disease, and mental retardation.
[0003] Maribavir is an oral UL97 protein kinase inhibitor. Although the drug has been approved in the United States for the treatment of post-transplant cytomegalovirus infection / disease, it will take time to observe the inhibitor's antiviral resistance. The gB-MF59 vaccine contains soluble recombinant gB and MF59 adjuvant. Although the vaccine performed best in clinical trials and showed partial protection against primary CMV, its immune response remains unclear, and the vaccine has only a mild effect in preventing viral infection. Therefore, alternative treatment strategies targeting different viral control points are still needed. The development of effective vaccines and treatments for cytomegalovirus remains an important medical need at this stage.
[0004] Effective vaccines or antiviral therapies should target the early steps of the cytomegalovirus infection cycle, including viral entry into host cells. The cell entry process of HCMV can be divided into two steps: receptor binding and membrane fusion. Glycoprotein B (gB) is a virion fusion protein of herpesviruses, including HCMV, and is involved in the membrane fusion process of virions and host cells during viral infection. It is essential for the infection of all types of target cells. gHgLpUL128-131a (pentamer) binds to CD147 and Neuropilin2 receptors on epithelial and endothelial cells, promoting the entry of virions through a pH-dependent endocytic pathway. Therefore, within the HCMV envelope, gB and pentamers were identified as the main targets of neutralizing antibody responses.
[0005] Although the pentamer component is able to induce extremely potent neutralizing antibodies during infection, it is completely ineffective in preventing fibroblast infection and has significantly reduced neutralizing activity against other cell types, so the protective effect of antibodies against the pentamer complex in humans remains to be demonstrated. In contrast, the glycoprotein gB is essential for infection of all types of target cells. Therefore, it is necessary to develop HCMV antibodies with high neutralizing activity by targeting gB as a target for neutralizing antibody responses. Summary of the invention
[0006] The present application aims to solve at least one of the technical problems existing in the prior art. To this end, the present application proposes an antibody binding to human cytomegalovirus gB protein and its application.
[0007] In a first aspect of the present application, there is provided an antibody or an antigen-binding fragment thereof that binds to human cytomegalovirus, comprising a heavy chain variable region and a light chain variable region;
[0008] A1) the heavy chain variable region comprises HCDR1 as shown in SEQ ID NO.9, HCDR2 as shown in SEQ ID NO.10 and HCDR3 as shown in SEQ ID NO.11, and the light chain variable region comprises LCDR1 as shown in SEQ ID NO.12, LCDR2 as shown in SEQ ID NO.13 and LCDR3 as shown in SEQ ID NO.14; or,
[0009] A2) The heavy chain variable region includes HCDR1 as shown in SEQ ID NO.15, HCDR2 as shown in SEQ ID NO.16, and HCDR3 as shown in SEQ ID NO.17, and the light chain variable region includes LCDR1 as shown in SEQ ID NO.18, LCDR2 as shown in SEQ ID NO.19, and LCDR3 as shown in SEQ ID NO.20.
[0010] The antibodies or antigen-binding fragments thereof according to the embodiments of the present application have at least the following beneficial effects:
[0011] The antibody or its antigen-binding fragment provided in the embodiments of the present application can bind to the gB protein of human cytomegalovirus with high affinity, and thus can be used to prepare drugs for preventing or treating human cytomegalovirus or diseases related to human cytomegalovirus infection, and can also be used for the detection of human cytomegalovirus or human cytomegalovirus gB protein.
[0012] In some embodiments of the present application, A1) the heavy chain variable region has an amino acid sequence with at least 85% sequence identity to the amino acid sequence shown in SEQ ID NO.2, and the light chain variable region has an amino acid sequence with at least 85% sequence identity to the amino acid sequence shown in SEQ ID NO.3; or,
[0013] A2) The heavy chain variable region has an amino acid sequence that is at least 85% identical to the amino acid sequence shown in SEQ ID NO.4, and the light chain variable region has an amino acid sequence that is at least 85% identical to the amino acid sequence shown in SEQ ID NO.5.
[0014] In some embodiments of the present application, the antibody or antigen-binding fragment thereof is selected from at least one of a full-length antibody, Fab, Fab', F(ab')2, Fv, scFv, Fc, Fd, and a domain antibody.
[0015] In some embodiments of the present application, it also includes a heavy chain constant region and a light chain constant region, the heavy chain constant region has an amino acid sequence that has at least 85% sequence identity with the amino acid sequence shown in SEQ ID NO.6; and / or the light chain constant region has an amino acid sequence that has at least 85% sequence identity with the amino acid sequence shown in SEQ ID NO.7.
[0016] In some embodiments of the present application, the antibody or antigen-binding fragment thereof is any one of a human antibody, a humanized antibody and a chimeric antibody.
[0017] In a second aspect of the present application, a biomaterial is provided, the biomaterial comprising any one of B1) to B4);
[0018] B1) a nucleic acid molecule encoding the aforementioned antibody or antigen-binding fragment thereof;
[0019] B2) an expression cassette containing the nucleic acid molecule of B1);
[0020] B3) a recombinant vector containing the nucleic acid molecule B1) or the expression cassette B2);
[0021] B4) A recombinant cell containing B1) a nucleic acid molecule or B2) an expression cassette or B3) a recombinant vector.
[0022] The third aspect of the present application provides a pharmaceutical composition, comprising C1) and C2):
[0023] C1) an effective dose of the aforementioned antibody or antigen-binding fragment thereof, or the aforementioned biological material;
[0024] C2) at least one of a pharmaceutically acceptable carrier, a diluent, a buffer and an excipient.
[0025] In a fourth aspect of the present application, a kit is provided, comprising the aforementioned antibody or antigen-binding fragment thereof.
[0026] The fifth aspect of the present application provides a use of the aforementioned antibody or antigen-binding fragment thereof, or the aforementioned pharmaceutical composition, or the aforementioned kit in the preparation of a product for diagnosis, prevention or treatment of human cytomegalovirus.
[0027] In a sixth aspect of the present application, a method for detecting human cytomegalovirus in a sample is provided, comprising contacting the sample with the aforementioned antibody or antigen-binding fragment thereof.
[0028] Additional aspects and advantages of the present application will be given in part in the description below, and in part will become apparent from the description below, or will be learned through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 It is the gel column chromatography and SDS-PAGE diagram of HCMV gB fusion protein in Example 1. Among them, the lane M of the SDS-PAGE diagram is the marker, the lane 1 is the +DTT reducing condition, and the lane 2 is the -DTT non-reducing condition.
[0030] Figure 2 (a) is the equilibrium dissociation constant between the CM1 antibody of Example 5 and the gB fusion protein, (b) is the equilibrium dissociation constant between the CM3 antibody of Example 5 and the gB fusion protein, and (c) is the equilibrium dissociation constant between the monoclonal antibody 3-25 and the gB fusion protein.
[0031] Figure 3 (a) is the result of the competitive binding experiment between CM1 in Example 6 and other antibodies, and (b) is the result of the competitive binding experiment between CM3 antibody in Example 6 and other antibodies.
[0032] Figure 4 These are the results of neutralizing activity testing of CM1 and CM3 antibodies in Example 7. DETAILED DESCRIPTION
[0033] The following will clearly and completely describe the concept of the present application and the technical effects produced in combination with the embodiments, so as to fully understand the purpose, features and effects of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of them. Based on the embodiments of the present application, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present application.
[0034] The embodiments of the present application are described in detail below. The described embodiments are exemplary and are only used to explain the present application, and should not be understood as limiting the present application.
[0035] In the description of this application, "several" means more than one, "more" means more than two, "greater than", "less than", "exceed", etc. are understood to exclude the number itself, and "above", "below", "within", etc. are understood to include the number itself. If there is a description of "first" or "second", it is only used for the purpose of distinguishing technical features, and cannot be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features or implicitly indicating the order of the indicated technical features.
[0036] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein are only for the purpose of describing the embodiments of this application and are not intended to limit this application.
[0037] In the description of the present application, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiments", "examples", "specific examples" or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.
[0038] The term "antibody" refers to an immunoglobulin that specifically binds to an antigen. Correspondingly, "antigen" refers to a target antigen to which an antibody can selectively bind, and specific types of target antigens include polypeptides, proteins, nucleic acids, lipids, carbohydrates, haptens or other natural or synthetic compounds. Specifically, in the present application, antigen refers to human cytomegalovirus gB protein, and an immunoglobulin that specifically binds to human cytomegalovirus gB protein refers to an immunoglobulin with a K of less than 500nM, 200nM, 100nM, 50nM, 20nM, 10nM, 5nM, 4nM, 3nM, 2nM, 1nM, 500pM, 200pM, 100pM D Immunoglobulins that bind to human cytomegalovirus gB protein. In addition, for antigens other than human cytomegalovirus gB protein, immunoglobulins as antibodies basically do not specifically bind to them, but this does not mean that antibodies cannot bind to other antigens, for example, immune cross-reactions are also known in the art.
[0039] Among them, K D is the equilibrium dissociation constant between antibody and antigen, K off With K on The ratio of K is expressed in molar concentration (M). D It can be used to measure the binding affinity between an antibody and its antigen. D The smaller the value, the stronger the affinity.D The value can be determined by any method known in the art, including but not limited to surface plasmon resonance (SPR) method, for example, SPR chip or related analysis system such as Biacore T200; biomembrane interferometry (BLI) method, for example, related detection system such as Octet Red96.
[0040] The types of antibodies specifically include monoclonal antibodies, polyclonal antibodies, multispecific antibodies, multivalent antibodies, etc. In addition, antibodies may be modified in a variety of ways, such as PEGylation, glycosylation, formation of antibody molecule conjugates (such as ADC), addition of purification tags, or fusion with other proteins.
[0041] Taking a full-length antibody as an example, it contains two heavy chains (HC) and two light chains (LC) interconnected by disulfide bonds or a polymer formed thereof. According to the conservative differences in the amino acid sequences, the heavy chain and the light chain can be divided into a variable region (V) and a constant region (C). Among them, each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (composed of domains CH1, hinge, CH2 and CH3), and each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The variable region includes three complementary determining regions (CDRs) and is separated by a framework region (FR), which is arranged from the amino terminus to the carboxyl terminus as FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4, so VH contains three CDRs: HCDR1, HCDR2, HCDR3, and VL contains three CDRs: LCDR1, LCDR2 and LCDR3.
[0042] The term "complementarity determining region" refers to the high-frequency mutation area in the variable region. The CDRs of a heavy chain and a light chain interact to form the antigen binding site of the full-length antibody, which is complementary to the three-dimensional structure of the antigen epitope. The high heterogeneity of CDR determines the diversity of antibodies, thereby recognizing different antigen epitopes.
[0043] Among them, the light chain of the antibody is divided into κ chain and λ chain. The heavy chain of the antibody can usually be divided into μ chain, δ chain, γ chain, α chain and ε chain, and antibodies are divided into five types: IgM, IgD, IgG, IgA and IgE. IgG and IgA can be further divided into different subclasses, such as IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2.
[0044] The term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, whereby the individual antibodies constituting the antibody population are substantially identical and bind to the same antigenic epitope, except for antibody variants resulting from mutations that may be present in very small amounts. It is understood that monoclonal antibodies are monospecific or polyspecific. Specifically, monoclonal antibodies typically bind to one antigenic epitope, but may also have polyspecificity. Accordingly, a "polyclonal antibody" refers to a collection of different antibodies directed against the same antigen, such as a collection of different antibodies produced by B lymphocytes, including mixed antibodies directed against different antigenic epitopes.
[0045] The term "multispecific" refers to an antibody that can bind to two or more different antigenic epitopes of the same antigen, or can bind to two or more different antigens or a combination thereof. Multispecific antibodies may have cross-reactivity to other related antigens, for example, to the same antigen from other species (homologous), or may bind to an epitope shared between two or more different antigens.
[0046] The term "epitope" refers to the part of an antigen that can specifically bind to an antibody, usually composed of amino acids or chemically active groups on the side chains, such as polar or non-polar or hydrophobic groups, and optionally has at least one of a specific three-dimensional structural feature and a specific charge feature.
[0047] Depending on the origin of the antibody, the antibody can be a human antibody, a humanized antibody or a chimeric antibody.
[0048] The term "human antibody" refers to an antibody whose variable region is derived from a human immunoglobulin sequence and, if the antibody has a constant region, the constant region is also derived from a human immunoglobulin sequence, wherein the human immunoglobulin sequence may be a human germline sequence or a mutant form thereof, such as a mutant form produced by random mutation or site-directed mutation.
[0049] The term "human antibody" refers to an antibody in which at least one CDR is derived from a non-human species antibody (donor antibody) and at least one FR is derived from a human antibody (recipient antibody). Among them, non-human species include other mammals, such as animals of the order Carnivora, Perissodactyla, Artiodactyla, Rodentia, Lagomorpha, and other animals of the order Primates, specifically non-human species such as dogs, cats, pigs, sheep, cattle, horses, rabbits, mice, monkeys, orangutans, gorillas, chimpanzees, etc.
[0050] The term "chimeric antibody" refers to antibodies in which different parts are derived from different animal species, such as antibodies whose variable regions are derived from one species and whose constant regions are derived from another species, specifically, the variable regions are derived from mouse antibodies and the constant regions are derived from human antibodies or vice versa. Chimeric antibodies are mainly used to reduce immunogenicity in applications and to increase the yield during preparation, for example, where mouse antibodies have a higher hybridoma yield but higher human immunogenicity, so that human / mouse chimeric antibodies are used. It is understood that chimeric antibodies also include situations in which different parts of an antibody are derived from different animal individuals.
[0051] In the case of known antibody complementary determining region sequences, those skilled in the art can easily replace part of the antibody sequence (e.g., constant region or framework region) with a sequence from another species by techniques such as DNA recombination to form a chimeric antibody or a humanized antibody, and substantially retain the binding specificity of the source antibody. For example, when the source antibody is a mouse antibody, its constant region or framework region can be replaced with a human antibody constant region, or conversely, when the source antibody is a human antibody, its constant region or framework region can be replaced with a mouse antibody constant region or framework region to reduce the immunogenicity of the antibody when used in different species or to utilize its specific functions, such as ADCC-related activity.
[0052] In order to further reduce the immunogenicity of the antibody or for other purposes, all sequences in the antibody molecule except the CDR sequence can be replaced with the corresponding sequence of another antibody molecule (from the same or different species) (which may include several amino acid mutations as appropriate), while substantially retaining the binding specificity of the source antibody.
[0053] The term "antigen-binding fragment" refers to an antibody fragment in an immunoglobulin that retains the ability to specifically bind to the antigen bound by the full-length antibody, which can be a synthetic, enzymatically obtained or genetically engineered polypeptide. Antibody binding fragments include at least one or more CDR fragments, and specific fragment types include Fab, Fab', F(ab')2, Fv, scFv, Fc, Fd, domain antibodies, etc. Among them, the Fab fragment contains the variable region and CH1 of a heavy chain and a light chain, for example, it can be a papain cleavage product of an antibody. The Fab' fragment contains the variable region and CH1 of a heavy chain and the regional fragment between CH1 and CH2 and a light chain. The F(ab')2 fragment is composed of two Fab' fragments connected by a disulfide bond between the heavy chains, for example, it can be a pepsin cleavage product of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and the hydrophobic interaction of the CH3 domain. The Fv fragment is composed of a heavy chain variable region and a light chain variable region. scFv is composed of a heavy chain variable region and a light chain variable region and a linker connecting the heavy chain variable region and the light chain variable region. Through correct folding, the heavy chain variable region and the light chain variable region interact through non-covalent bonds to form an Fv segment, so that scFv can better retain its affinity activity for the antigen. Fc is composed of two heavy chain fragments including CH1 and CH2. Fd is composed of a heavy chain variable region and CH1. Domain antibodies are composed of heavy chain variable regions or light chain variable regions. In some cases, the heavy chain variable regions can be connected by a linker to form a bivalent domain antibody. The heavy chain variable regions of the bivalent domain antibodies can target the same or different antigens. Domain antibodies were first discovered in camels. They naturally lack light chains, but still have antigen binding ability. Compared with ordinary antibody molecules, domain antibodies have some advantages, such as better stability against pH, heat, and proteases, and can target and bind to antigen epitopes on antigen molecules that are difficult for ordinary antibody molecules to access.
[0054] Methods for preparing antibodies are known in the art, including but not limited to separating cells expressing specific antibodies after immunizing animals with antigens (e.g., preparing antibodies by hybridoma technology), screening antibody technology using phage antibody libraries, transforming cells by genetic engineering technology and expressing antibody molecules, etc. In some specific embodiments, the present application provides a method for expressing antibodies or antigen-binding fragments thereof in host cells, and the host cells can be specifically mammalian cells, such as mice, rats, pigs, sheep, monkeys, orangutans or human cells. In some embodiments, the mammalian cells are selected from at least one of 293F cells and MCR-5 cells, thus providing a method for preparing antibodies or antigen-binding fragments thereof by introducing a recombinant expression vector comprising a heavy chain variable region and a light chain variable region encoding an antibody or antigen-binding fragment thereof into host cells such as 293F cells and MCR-5 cells.
[0055] The term "human cytomegalovirus (HCMV)", also known as cytomegalovirus (CMV) or human herpesvirus type 5 (HHV5), is a β-herpesvirus that can cause lifelong infection in humans of all ages. Specifically, HCMV can be at least one of the strains AD169, Davis, Merlin, TB40E, Toledo, Towne, VR1814, etc. Correspondingly, "human cytomegalovirus gB protein" refers to the gB protein (gpUL55) of human cytomegalovirus, which is a type III viral fusion protein that has structural similarities to the gB proteins of herpes simplex virus type 1 (HSV-1) and Epstein-Barr virus (EBV) and is required for HCMV cell entry and cell-to-cell transmission. Although there are reports that gB can bind to EGFR and PDGFRα, there are also reports that gB promotes HCMV trans-entry as a viral fusion protein rather than a receptor-binding protein.
[0056] The term "sequence identity" refers to the amount of consistency between two amino acid sequences (e.g., a query sequence and a reference sequence), generally expressed as a percentage. Typically, before calculating the percentage of consistency between two amino acid sequences, a sequence alignment is performed and gaps are introduced if any. If the amino acid residues in the two sequences are the same at a certain alignment position, the two sequences are considered to be consistent or matched at that position; if the amino acid residues in the two sequences are different, they are considered to be inconsistent or mismatched at that position. In some algorithms, the number of matching positions is divided by the total number of positions in the alignment window to obtain sequence consistency. In other algorithms, the number of gaps and / or the length of the gaps are also taken into account. The specific alignment method can use the publicly available alignment software BLAST (available on the webpage ncbi.nlm.nih.gov) to obtain the best sequence alignment and calculate the sequence consistency between the two amino acid sequences using the default settings.
[0057] The term "nucleic acid molecule" refers to at least one of DNA and RNA of genome, mRNA, cDNA or synthetic origin. It is understood that those skilled in the art can mutate or modify the nucleotide sequence of the nucleic acid molecule by known methods, such as directed evolution and point mutation, as long as the antibody or antigen-binding fragment thereof encoded by the mutated or modified nucleic acid molecule has the same function, they are all derived from the nucleotide sequence of the embodiment of the present application and belong to the nucleic acid molecule of the embodiment of the present application.
[0058] The term "expression cassette" refers to a construct containing the necessary regulatory elements for the expression of the contained nucleic acid molecule in a recombinant cell. Specific regulatory elements include promoters, polyadenylation sites, etc.
[0059] The term "recombinant vector" refers to a molecule containing all elements for replication, integration, amplification and / or expression of the nucleic acid molecules contained in the recombinant cell. All elements include, but are not limited to, promoters, polyadenylation sites, terminators, replication initiation sites, transcription initiation sequences, enhancers, selection elements, reporter genes, etc. For example, antibiotic resistance genes or selection marker genes (such as ampicillin resistance gene AmpR, thymidine kinase gene TK, etc.) for screening and target protein coding sequences can be inserted into the multiple cloning site (MCS). Optional recombinant vector types include plasmids, bacteriophages, lentiviruses, adenoviruses, adeno-associated viruses, etc.
[0060] The term "recombinant cell" refers to a cell in which a nucleic acid molecule is replicated, integrated, amplified and / or expressed. Recombinant cells include, but are not limited to, bacteria, fungi, insect cells, plant cells, and animal cells. Among them, bacteria, for example, can be Escherichia coli or Bacillus subtilis, fungi, for example, can be yeast or Aspergillus, insect cells, for example, can be S2 Drosophila cells or Sf9 cells, plant cells, for example, can be cells of Arabidopsis thaliana or tobacco, and animal cells, for example, can be mammalian cells, such as mice, rats, pigs, sheep, monkeys, orangutans, or human cells, specifically 293T cells, 293F cells, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells, etc. It is understood that these recombinant cells can all be non-reproductive materials.
[0061] The first aspect of the embodiments of the present application relates to an antibody or an antigen-binding fragment thereof that binds to human cytomegalovirus gB protein, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises three CDRs, namely HCDR1, HCDR2 and HCDR3; and the light chain variable region comprises three CDRs, namely LCDR1, LCDR2 and LCDR3. Among them, HCDR1 to HCDR3 and LCDR1 to LCDR3 are respectively selected from the following groups:
[0062] A1) HCDR1 with the amino acid sequence shown in SEQ ID NO.9: EFSFSHHG;
[0063] HCDR2 with the amino acid sequence shown in SEQ ID NO.10: ISSDGTNQ;
[0064] HCDR3 with the amino acid sequence shown in SEQ ID NO.11: AREGRCSGNNCYSGLPDY;
[0065] LCDR1 having an amino acid sequence as shown in SEQ ID NO.12: QSVGGY;
[0066] LCDR2 having an amino acid sequence as shown in SEQ ID NO. 13: DAS;
[0067] LCDR3 having an amino acid sequence as shown in SEQ ID NO. 14: LQRSNWPPLT;
[0068] A2) HCDR1 with the amino acid sequence shown in SEQ ID NO.15: GYTFSGYW;
[0069] HCDR2 with the amino acid sequence shown in SEQ ID NO.16: IYPGDSDT;
[0070] HCDR3 having an amino acid sequence as shown in SEQ ID NO.17: AVLGPVSAIVEDYSGFDI;
[0071] LCDR1 having an amino acid sequence as shown in SEQ ID NO. 18: QGISSY;
[0072] LCDR2 having an amino acid sequence as shown in SEQ ID NO. 19: GAT;
[0073] The amino acid sequence of LCDR3 is shown in SEQ ID NO.20: QRLKSYPYT.
[0074] Those skilled in the art can also understand that, based on the specific antibody sequences provided herein, a small number of amino acids can be replaced, deleted, added, and the binding ability or biological activity of the resulting products to the corresponding antigens can be verified or screened to obtain the corresponding variants of the antibodies binding to the gB protein provided in the embodiments of the present application, and these variants should also be included in the scope of the embodiments of the present application.
[0075] Therefore, in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment thereof corresponding to the CDR combination of A1) has an amino acid sequence with at least 85% (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) sequence identity to the amino acid sequence as shown in SEQ ID NO.2, and the light chain variable region has an amino acid sequence with at least 85% (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) sequence identity to the amino acid sequence as shown in SEQ ID NO.3; the heavy chain variable region of the antibody or antigen-binding fragment thereof corresponding to the CDR combination of A2) has an amino acid sequence with at least 85% (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) sequence identity to the amino acid sequence as shown in SEQ ID NO. The light chain variable region has an amino acid sequence that has at least 85% (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) sequence identity to the amino acid sequence shown in SEQ ID NO.4, and the light chain variable region has an amino acid sequence that has at least 85% (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) sequence identity to the amino acid sequence shown in SEQ ID NO.5.
[0076] In some embodiments, the antibody or antigen-binding fragment thereof is selected from at least one of a full-length antibody, Fab, Fab', F(ab')2, Fv, scFv, Fc, Fd, and a domain antibody. In some embodiments, the antibody or antigen-binding fragment thereof further comprises at least one of a heavy chain constant region and a light chain constant region. It is understood that the heavy chain constant region and the light chain constant region may be full-length or partial fragments thereof, such as CH1, CH2, etc. In some specific embodiments, the heavy chain constant region has an amino acid sequence having a sequence identity of at least 85% (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) with the amino acid sequence shown in SEQ ID NO.6. In some specific embodiments, the light chain constant region has an amino acid sequence with at least 85% (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) sequence identity to the amino acid sequence shown in SEQ ID NO. 7. In some embodiments, the antibody or antigen-binding fragment thereof is any one of a human antibody, a humanized antibody, and a chimeric antibody.
[0077] In some specific embodiments, the antibody or antigen-binding fragment thereof further comprises a tag sequence at the N-terminus and / or C-terminus, including a tag sequence that facilitates dissolution and / or purification. Specifically, the tag sequence comprises at least one of a His tag, a GGGS sequence, a FLAG tag, a strep tag, a nus tag, a maltose binding protein, and a GST tag. It is understood that one or more tag sequences may be included; multiple tag sequences may include a combination of multiple identical tag sequences, or a combination of multiple different tag sequences.
[0078] The second aspect of the embodiments of the present application relates to a biomaterial, which may be a nucleic acid molecule encoding the aforementioned antibody or its antigen-binding fragment; an expression cassette containing the nucleic acid molecule; a recombinant vector containing the nucleic acid molecule or the expression cassette; a recombinant cell containing the nucleic acid molecule or the expression cassette or the recombinant vector.
[0079] The third aspect of the embodiments of the present application relates to a pharmaceutical composition, including an effective dose of an antibody or an antigen-binding fragment thereof or a biomaterial. In some embodiments, the pharmaceutical composition further includes a pharmaceutically acceptable carrier. Among them, the pharmaceutically acceptable carrier includes solid or liquid diluents, fillers, antioxidants, stabilizers and other substances that can be safely administered, which are suitable for human and / or animal administration without excessive adverse side effects, and are suitable for maintaining the vitality of the drug or active agent located therein. In some embodiments, the pharmaceutical composition also includes other substances that have a preventive or therapeutic effect on human cytomegalovirus or its related diseases or symptoms or complications, such as antiviral drugs for human cytomegalovirus, such as ganciclovir, valganciclovir, cidofovir, letermovir, maribavir, sodium foscarnet, fomivirson, etc.; or other antibodies to human cytomegalovirus, such as LJP538, LJP539, TCN202, etc.; or a combination of several. In some embodiments, the pharmaceutical composition can be administered in the form of any one or more of powders, granules, powders, tablets, capsules, gels, suspensions, drops, pills, injections, suppositories, aerosols, oral liquids, ointments, emulsions, and lavage agents, for example, by at least one of oral administration, sublingual administration, nasal administration, rectal administration, inhalation administration, transdermal administration, intraperitoneal injection, subcutaneous injection, and intramuscular injection.
[0080] It is understood that, for the ingredients in the pharmaceutical composition, it can be administered to the subject simultaneously or sequentially. Wherein, the effective dose refers to the amount of the active compound (such as antibody) sufficient to cause the biological or medical response desired by the clinician in the subject, and specifically, the effective dose can be determined by those skilled in the art according to factors such as the route of administration, the subject's weight, age, and condition. For example, a typical daily dose range can be 0.01 mg to 100 mg of active ingredient per kg body weight, such as 0.01 mg, 0.02 mg, 0.05 mg, 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 50 mg, 100 mg.
[0081] A fourth aspect of the embodiments of the present application relates to a kit, which includes the aforementioned antibody or antigen-binding fragment thereof.
[0082] In some embodiments, the kit can be any one of a detection plate, a detection chip, a detection test strip, etc. for human cytomegalovirus or human cytomegalovirus gB protein.
[0083] In some embodiments, the antibody or antigen-binding fragment thereof can be used to form a kit in the form of a solid (such as a lyophilized powder), a liquid (such as a solution), or directly coated on a substrate (such as a test paper or a chip).
[0084] In some embodiments, the kit detects human cytomegalovirus or human cytomegalovirus gB protein by any one of immunochromatography, enzyme-linked immunosorbent assay, chemiluminescence, electrochemiluminescence, etc. Enzyme-linked immunosorbent assay includes but is not limited to any one of direct method, indirect method, sandwich method and competitive method. Immunochromatography includes but is not limited to any one of fluorescent microsphere immunochromatography, colloidal gold immunochromatography, latex microsphere immunochromatography, time-resolved fluorescent microsphere immunochromatography, magnetic microsphere immunochromatography and quantum dot immunochromatography.
[0085] In some embodiments, the antibody or antigen-binding fragment thereof can be used as at least one of a coating antibody and a detection antibody in the kit.
[0086] In some embodiments, the antibody or antigen-binding fragment thereof is bound to a solid substrate such as magnetic beads, microspheres, microplates, nitrocellulose membranes, microfluidic chips, etc.
[0087] In some embodiments, a detectable marker is coupled to the antibody or its antigen-binding fragment, or a separate detectable marker that can be coupled to the antibody or its antigen-binding fragment is also included in the kit. Specifically, the detectable marker can be at least one of a radionuclide, a fluorescent substance, a chemiluminescent substance, a colored substance, an aggregation-induced luminescent substance, a micro-nanoparticle, an enzyme, and the like.
[0088] The fifth aspect of the embodiments of the present application relates to the use of an antibody or an antigen-binding fragment thereof, or a pharmaceutical composition, or a kit in the preparation of a product for diagnosis, prevention or treatment of human cytomegalovirus.
[0089] Specifically, the antibody or its antigen-binding fragment can be used to prepare a product for diagnosis, prevention or treatment of human cytomegalovirus, the pharmaceutical composition can be used to prepare a product for prevention or treatment of human cytomegalovirus, and the kit can be used to prepare a product for diagnosis of human cytomegalovirus.
[0090] The present application also relates to an antibody or an antigen-binding fragment thereof, or a pharmaceutical composition, or a kit for use in diagnosing, preventing or treating human cytomegalovirus infection. Specifically, the antibody or its antigen-binding fragment can be used to diagnose, prevent or treat human cytomegalovirus infection, the pharmaceutical composition can be used to prevent or treat human cytomegalovirus infection, and the kit can be used to diagnose human cytomegalovirus infection.
[0091] The embodiments of the present application also relate to a method for diagnosing, preventing or treating human cytomegalovirus infection, comprising contacting an antibody or an antigen-binding fragment thereof, or a pharmaceutical composition, or a kit with a subject. Specifically, a method for diagnosing, preventing or treating human cytomegalovirus infection comprises contacting an antibody or an antigen-binding fragment thereof with a subject; a method for preventing or treating human cytomegalovirus infection comprises administering a pharmaceutical composition to a subject; a method for diagnosing human cytomegalovirus infection comprises administering a kit to a subject.
[0092] A sixth aspect of the embodiments of the present application relates to a method for detecting human cytomegalovirus in a sample, the method comprising contacting the sample with the aforementioned antibody or antigen-binding fragment thereof.
[0093] In some embodiments of the present application, the method for detecting human cytomegalovirus in a sample is a method for non-disease diagnosis or treatment purposes, such as virus monitoring analysis, etc. The transmission routes of human cytomegalovirus include body fluid transmission, such as blood, urine, saliva, breast milk, tears, semen and vaginal secretions, as well as organ, bone marrow, stem cell transplantation and childbirth, which may cause the spread of the virus. Therefore, the virus can be monitored by testing samples including the above-mentioned situations.
[0094] In some embodiments of the present application, the sample includes a biological sample. In some embodiments, the biological sample includes but is not limited to at least one of body fluids (e.g., blood, tissue fluid, lymph, cerebrospinal fluid, urine, sweat, sputum, saliva, gastric juice, intestinal juice, pancreatic juice, bile, prostatic fluid, vaginal secretions, semen, serous cavity effusion, joint cavity effusion, bronchoalveolar lavage fluid, amniotic fluid, etc.), skin, feces, intestinal contents, histological samples (e.g., samples obtained by surgery, endoscopy or percutaneous puncture biopsy).
[0095] The antibodies or antigen-binding fragments thereof provided in the examples of the present application can be used for the development of antibody conjugates targeting gB protein.
[0096] The antibody or antigen-binding fragment thereof provided in the embodiments of the present application can specifically bind to human cytomegalovirus gB protein, that is, human cytomegalovirus gB protein is used as the target antigen of the antibody. Due to the antigen-binding specificity of the antibody provided in the embodiments of the present application, the antibody can be used to detect whether human cytomegalovirus is present in a sample (such as blood) from a subject. Accordingly, the embodiments of the present application provide an HCMV detection kit that can include the antibody or antigen-binding fragment thereof of the present embodiment.
[0097] Specifically, in the examples of the present application, HCMV gB fusion protein was used as bait, and two human monoclonal antibodies were isolated from adult peripheral blood mononuclear cells, named CM1 and CM3. Both antibodies can bind to HCMV gB protein with high specificity, so these two monoclonal antibodies can be used for HCMV diagnosis and antigen quantification. In addition, CM1 monoclonal antibody has high neutralizing activity against at least HCMV AD169 strains, and can be used for the prevention and treatment of HCMV.
[0098] The present invention is further described below through specific examples.
[0099] Example 1: Expression and purification of HCMV gB protein and evaluation of volunteer serum
[0100] The HCMV gB (GenBank: CAA35414.1) protein sequence was retrieved from the NCBI database. Some mutation sites (Y155G, I156H, Y157R, Y206H, S238N, W240T, L241T, Y242H and C246S) were introduced into the gB protein (32-692aa) to improve the expression and stability of the gB protein, and the HRV 3C restriction site, 8×His tag and Twin-Strep tag were introduced at the C-terminus. The coding gene corresponding to the above protein sequence was optimized by human codons and constructed into the vector pCAGGS plasmid. After 5-7 days of expression in suspended mammalian cells 293F, the supernatant was collected and filtered with a 0.22μm filter membrane. The protein was purified using an affinity column HisTrap HP (5mL, GE healthcare) and a gel filtration column Superose6 10 / 30GL (GE healthcare). The protein was concentrated to 10 mg / mL, quickly frozen in liquid nitrogen and stored at -80°C for later use.
[0101] The amino acid sequence of the gB protein with the mutation site introduced and the above-mentioned tag fused is as follows:
[0102] MNPLLILTFVAAALAAPFDDDDKTSSTHNGSHTSRTTSAQTRSVYSQHVTSSEAVSHRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINEDLDEGIMVVYKRNIVAHTFKVRVYQKVLTFRRSYAGHRTTYLLGSNTEYVAPPMWEIHHINKFAQCYSSYSRVIGGTVFVAYHRDSHENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGNTTTHRETSNLNCMLTITTARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPNAAPETHRLVAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSKKQEVNMSDSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVELERLANRSSLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAWCVDQRRTLEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESPGRCYSRPVVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRMIDLSSISTVDSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEEIMREFNSYKQRLEVLFQGPHHHHHHHHGSSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK (SEQ ID NO.1).
[0103] The size and purity of the target protein were determined according to the elution position of gel filtration chromatography and the results of SDS-PAGE. The results are as follows Figure 1As shown, the protein peak position is at 15mL, which is consistent with the theoretical molecular weight of gB protein ~240kDa, which is also consistent with the molecular weight of gB protein showing trimer. When SDS-PAGE is not added with DTT, the disulfide bonds in the monomeric gB protein are not opened, so the band size is about 240kDa; when DTT is added, the disulfide bonds are opened due to the reduction effect, showing three bands, the upper band position is about 110kDa, the middle band is about 72kDa, and the lower band position is about 34kDa. The bands are all diffuse, which is formed by glycosylation and is related to the amino acids containing glycosylation sites in the protein sequence.
[0104] HCMV gB protein was coated in the microplate, and 100 μL was added to each well at a concentration of 2 μg / mL, and incubated at 4°C overnight. The next day, the plate was washed 3 times with PBST. Then 2% BSA was added at 150 μL / well for blocking, incubated at 37°C for 2 hours, and the plate was washed 3 times with PBST. Subsequently, 100 μL / well of multiple healthy adult volunteer sera diluted in multiple ratios (1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12400) were added, incubated at 37°C for 2 hours, and the plate was washed 3 times with PBST. Then, goat anti-human IgG (Fc specific) horseradish peroxidase-labeled secondary antibody was added at 100 μL / well, diluted 1:5000, incubated at 37°C for 1 hour, and the plate was washed 3 times with PBST. Add 100 μL / well of TMB substrate for color development, react in the dark for 10 min, then add 50 μL 2M H2SO4 to terminate the reaction. Measure OD450 and perform data processing.
[0105] In this example, the antibody titers against HCMV gB protein antigen in the sera of multiple volunteers were titrated by ELISA method. By analyzing the OD values, two volunteers with better serum antibody neutralization binding titers were selected for the next experiment.
[0106] Example 2: Isolation of HCMV gB protein-specific memory B cells
[0107] With the informed consent of two volunteers, 3-10 mL of blood was collected from each of them and PBMCs were isolated. 7 / mL) was incubated on ice with 200nM gB protein prepared in Example 1 for half an hour; then washed twice with PBS, and then mixed with the following antibodies (all purchased from BD): anti-human CD3 / PE-Cy5, anti-human CD16 / PE-Cy5, anti-human CD235a / PE-Cy5, anti-human CD19 / APC-Cy7, anti-human CD27 / Pacific Blue, anti-human CD38 / APC, anti-human IgG / FITC, and anti-His / PE. After incubation on ice for half an hour, it was washed twice with PBS. Subsequently, PBMCs were sorted with FACSAria III, and PE-Cy5 was collected. - APC - APC-Cy7 + Pacific Blue + FITC + PE + The cells (i.e., memory B cells) were directly collected into a 96-well plate at 1 cell / well.
[0108] Example 3: Single B cell PCR and cloning of human monoclonal antibody IgG1
[0109] The cells obtained in Example 2 were reverse transcribed by Superscript III reverse transcriptase (Invitrogen), and the reaction conditions were 55°C, 60min. The reverse transcription product was used as a template, and PCR was performed using HotStar TapPlus enzyme (QIAgen) to amplify the antibody variable region sequence (PCRa), and the reaction conditions were as follows: 95°C, 5min; 95°C, 30s, 55°C (heavy chain / κ chain) / 50°C (λ chain), 30s, 72°C, 90s, 35 cycles, 72°C, 7min. This was used as a template for another round of PCR (PCRb), and the conditions were as follows: 95°C, 5min; 95°C, 30s, 58°C (heavy chain) / 60°C (κ chain) / 64°C (λ chain), 30s, 72°C, 90s, 35 cycles, 72°C, 7min. 1.2% agarose gel electrophoresis was used to separate the PCR products, and the 400-500bp band was excised and recovered and sent to a sequencing company for sequencing. The sequencing results were analyzed on the IgBLAST website.
[0110] A total of two paired antibodies were obtained: CM1 and CM3. According to the sequencing results, the amino acid sequence of the heavy chain variable region of CM1 is SEQ ID NO.2, and the amino acid sequence of the light chain variable region is SEQ ID NO.3; the amino acid sequence of the heavy chain variable region of CM3 is SEQ ID NO.4, and the amino acid sequence of the light chain variable region is SEQ ID NO.5.
[0111] EVQLVESGGGVVHPGGSLRLSCAASEFSFSHHGIHWVRQAPGMGLEWVAVISSDGTNQQYADSVRGRFTVSRDNSKYTLYLHLTSLRVEDTALYFCAREGRCSGNNCYSGLPDYWGQGIWVTVSS(SEQ ID NO.2);
[0112] EIVLTQSPATLSLSPGERATLSCRASQSVGGYLAWYQQKPGRAPRLLIYDASNRASGIPARFGGGSGTDFTLTISSLEPEDFAVYYCLQRSNWPPLTFGGGTKVEIR(SEQ ID NO.3);
[0113] EVQLVQSGAEVKKPGESLIISCQGSGYTFSGYWIAWVRQMPGKGLEWMGIIYPGDSDTTYSPSFQGQVTISADKSISTAYLQWSSLKVSDSAMYYCAVLGPVSAIVEDYSGFDIWGQGTMVTVSS(SEQ ID NO.4);
[0114] DIQMTQSPSFLTASVGDRVTITCRASQGISSYLAWYQQKPGKAPELLIYGATTLRSGVPSRFSGSGSGTEFTLTISSLQPEDSAAYYCQRLKSYPYTFGQGTKLEIK (SEQ ID NO. 5).
[0115] Among them, the amino acid sequences of HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3 in the heavy chain variable region of CM1 are shown in SEQ ID NOs. 9, 10, 11, 12, 13, and 14, respectively; the amino acid sequences of HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3 in the heavy chain variable region of CM3 are shown in SEQ ID NOs. 15, 16, 17, 18, 19, and 20, respectively.
[0116] The light chain sequencing results of the two antibodies were compared with the germline genes, and it was determined that both CM1 and CM3 used CLκ.
[0117] In order to obtain human antibodies for subsequent evaluation, we designed a full anti-IgG1 construct. The strategy is as follows:
[0118] Heavy chain: CMV promoter-SacI-signal peptide (SP)-heavy chain variable region (VH)-heavy chain constant region (CH)-KpnI;
[0119] Light chain κ: CMV promoter-SacI-signal peptide (SP)-light chain variable region (VK)-light chain constant region (CLκ)-KpnI.
[0120] The correct variable region sequence was analyzed and connected with the corresponding constant region of heavy chain CH and light chain CLκ by bridge PCR, and cloned into the expression vector pCAGGS to obtain a recombinant plasmid containing the light and heavy chain coding genes of a specific antibody; wherein, the light and heavy chain variable regions were connected to the vector containing the constant region using the restriction sites SacI and KpnI. The amino acid sequence of the heavy chain constant region CH is as shown in SEQ ID NO.6; the amino acid sequence of the light chain constant region CLκ is as shown in SEQ ID NO.7, and the amino acid sequence of the signal peptide (SP) is as shown in SEQ ID NO.8.
[0121] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO.6);
[0122] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECS(SEQ ID NO.7);
[0123] ETDTLLLWVLLLWVP (SEQ ID NO. 8).
[0124] Example 4: Expression and purification of monoclonal antibodies
[0125] The pCAGGS plasmid containing the heavy chain and light chain coding sequences was co-transfected into 293F cells. 220 mM MVPA was added 24 h after transfection and culture was continued for 5 days. The cells were harvested, the supernatant was collected by centrifugation, filtered with a 0.22 μm filter membrane, and passed through a HiTrap Protein A HP (5 ml, GE Healthcare) column at a speed of 2 mL / min.
[0126] According to the operating instructions of the affinity column, the initial elution and purification of the antibody was completed. The antibody was further purified using a gel filtration column (superdex200PG, GE Healthcare) to obtain a high-purity antibody. The purified monoclonal antibody was cleaved by papain (Thermo) according to the product instructions, and the Fab fragment was purified by HiTrap Protein A HP and gel filtration chromatography, and finally concentrated and stored at -80°C for future use.
[0127] Example 5: Antibody Binding Performance Detection
[0128] The Octet Red96 system (ForteBio) was used to detect the interaction between the purified antibodies and the fused gB protein by biomembrane interferometry (BLI). CM1 and CM3 were loaded at a concentration of 10 μg / mL using proteinA sensor, then bound to 12.5-400 nM gB protein for 180 s, dissociated for 600 s, and the sensor was regenerated using 10 mM Glycine (pH 1.5). All proteins used in the experiment were exchanged into PBS buffer, and the detection buffer was used to measure the binding of gB protein. The apparent equilibrium dissociation constant (K) of the interaction between gB protein and CM1 and CM3 antibodies was calculated using Octet Red96 evaluation software. D value).
[0129] The results are as follows Figure 2 As shown in Figure 2, both CM1 and CM3 can bind to HCMV gB fusion protein with high affinity, and the K of CM1 binding to HCMV gB fusion protein is D =2.01 nM, K of CM3 binding to HCMV gB fusion protein D =3.16 nM, which has the same order of magnitude affinity as previously reported positive mAbs 3-25 and SM5-1. For example, the K D It is 3.26nM.
[0130] Example 6: Detection of monoclonal antibody binding epitopes
[0131] HCMV gB protein is currently divided into five antigenic epitopes, I, II, III, IV and V. Among them, the antigenic binding epitope of 3-25 (PDB: 5C6T) is AD2, the antigenic binding epitope of 1G2 (PDB: 6UOE) is AD-5, and the antigenic binding epitope of SM5-1 (PDB: 4OT1) is AD4. Using biomembrane interference technology Octet Red96 to explore whether CM1 and CM3 have competitive binding with the positive control antibodies of the above three different binding epitopes can preliminarily determine whether CM1 and CM3 interact with these three antigenic epitopes. The operation steps are as follows:
[0132] 10 μg / mL gB protein was immobilized on the Octet NTA sensor and first combined with the test antibody CM1 / CM3, positive control antibodies (1G2, 3-25 and SM5-1) and negative control antibody (Palivizumab, HCMV antibody) for 900 s to fully bind to gHgLgO protein to reach saturation state, and then competed with CM1 / CM3 for binding.
[0133] The results are as follows Figure 3 As shown, after the CM1 antibody in (a) binds to gB saturation, it can still bind to 1G2 and SM5-1, indicating that the binding epitope of the CM1 antibody is not on AD-5 and AD-4, but it cannot continue to bind to 3-25, which suggests that CM1 may have a competitive binding relationship with 3-25 and bind to the AD2 epitope. After the CM3 antibody in (b) binds to gB saturation, it can still bind to 3-25, 1G2 and SM5-1, indicating that the binding epitope of the CM3 antibody is not on AD2, AD5 and AD4, which suggests that CM3 may bind to other unknown epitopes.
[0134] Example 7: Neutralizing activity detection of antibodies
[0135] The neutralizing activity of antibodies was detected by microneutralization method. The detailed steps are as follows:
[0136] 1. Cell and virus preparation
[0137] MRC-5 cells were plated in 96-well plates 12 to 16 hours in advance and cultured in DMEM medium containing 10% FBS. Antibody neutralization experiments were performed the next day after the cells grew to a confluence of more than 90%.
[0138] Diluted antibodies: CM1 and CM3 antibodies. After purification, each antibody was filtered to sterile conditions. The antibody was added to a 96-well plate and diluted 3-fold. At least 75 μL of each well was diluted with 2% FBSDMEM culture medium.
[0139] Dilute the virus: thaw the HCMV AD169 strain from the -80°C freezer, dilute the virus with 2% FBSDMEM medium at a dilution multiple of 1 mL to 20 mL, and then add it to the 96-well plate of the antibody. The final titer is 1×10 3 PFU.
[0140] 2. Virus and Antibody Incubation
[0141] Mix the diluted virus and antibody in a volume ratio of 1:1 and incubate in a 37°C CO2 incubator for 1 hour.
[0142] The PBS in the cells was aspirated, and the virus and cell supernatant mixture was added to the cells at 150 μL per well. After incubation at 37°C for 1 hour, the medium was replaced with 2% FBSDMEM medium, and the cells were cultured in an incubator for 96 hours. Each gradient was set with at least two replicate wells, a total of 11 gradients, and a virus well control was set.
[0143] 3.CQ1 fluorescence detection
[0144] Take out the 96-well plate, use CQ1 to count the fluorescence quantity in each well, and calculate the IC50 value.
[0145] Results Reference Figure 4 For HCMV AD169 strain, the half inhibitory concentration IC50 of antibody CM1 was 0.41 μg / mL, while CM3 did not show a neutralizing effect.
[0146] Example 8
[0147] This embodiment provides an HCMV diagnostic kit, including HCMV standards of different concentration gradients, a coating plate, an HCMV primary antibody, an enzyme-labeled HCMV secondary antibody, a BSA blocking solution, a color developer A solution, a color developer B solution, a stop solution, and the like.
[0148] The preparation process of the pre-coated plate is as follows: the purified HCMV primary antibody is diluted with a carbonate buffer solution of pH 9.6 to obtain a mixed solution with a concentration of 5 μg / mL, and the 96-well plate is coated with 0.1 mL per well. After incubation at 4°C for 21 hours, the liquid in the well is discarded, and the wells are washed and patted dry; then BSA blocking solution is added to each well, 0.1 mL per well, incubated at 37°C for 2 hours, the liquid in the well is discarded, and the wells are washed and patted dry to obtain a pre-coated plate.
[0149] The primary HCMV antibody was a mouse anti-HCMV monoclonal antibody.
[0150] The enzyme-labeled HCMV secondary antibody was labeled with HRP by sodium periodate oxidation method, and the HCMV secondary antibody was CM1.
[0151] The stop solution was 2M sulfuric acid.
[0152] The method of using the kit is as follows:
[0153] Add 75 μL of sample or HCMV standard to each well, set up negative control and blank control, incubate at 37℃ for 1h, discard the liquid in the well, wash and pat dry. Then add 25 μL of enzyme-labeled HCMV secondary antibody to each well, incubate at 37℃ for 1h, discard the liquid in the well, wash and pat dry. Then add 100 μL of color developer A solution and color developer B solution to each well, color at 37℃ for 10min, and add 50 μL of stop solution to each well. At a wavelength of 450nm, zero the blank well and read the OD value of each well.
[0154] The quantitative method is as follows: a standard curve is drawn according to the OD values of HCMV standards of different concentrations and the linear range is determined, and the OD value of the sample is substituted into the standard curve to obtain the HCMV concentration in the sample.
[0155] The qualitative method is as follows: twice the OD value of the negative control is set as the critical OD value. When the OD value of the sample is greater than the critical OD value, it is determined to be HCMV antigen positive, otherwise it is negative.
[0156] Example 9
[0157] This embodiment provides a HCMV diagnostic kit, which is different from Embodiment 8 in that the HCMV secondary antibody is CM3.
[0158] In Examples 8 to 9, the detection limit LOD=3SD / b was calculated according to the standard curve, where SD is the standard deviation of the blank control and b is the slope of the standard curve. The results showed that all three had lower detection limits. At the same time, clinical samples identified as negative and positive for nucleic acid were tested to determine the false positive and false negative conditions of the kit. The results showed that the HCMV diagnostic kits of Examples 7 to 9 all had good specificity and sensitivity.
[0159] Example 10
[0160] This embodiment provides a HCMV colloidal gold test strip, comprising a sample pad, a colloidal gold pad, a nitrocellulose membrane, a water-absorbing paper, and a PVC substrate, which are arranged in sequence in pairs. A spotting hole is provided on the sample pad.
[0161] The colloidal gold pad is coated with colloidal gold-labeled mouse anti-HCMV monoclonal antibody, and the nitrocellulose membrane is provided with a quality control line (C line) and a detection line (T line). The quality control line is coated with sheep anti-mouse IgG antibody, and the detection line is coated with CM1 antibody.
[0162] During the test, add 200 μL of the sample to the spotting well, react for 15 minutes and observe the results; if both the C line and the T line have bands, it is positive; if only the C line has a band, it is negative; if there is no band on the C line, the result is invalid.
[0163] Embodiment 11
[0164] This embodiment provides a HCMV colloidal gold test strip, which is different from Embodiment 10 in that the detection line is coated with CM3 antibody.
[0165] The HCMV colloidal gold test strips of Examples 10 to 11 were tested with HCMV standards of different concentrations, and the lowest concentration of the standard when the T line appeared was determined as the detection sensitivity of the test strip. At the same time, clinical samples identified as negative and positive for nucleic acid were tested to determine the false positive and false negative conditions of the test strip. The results showed that the test strips of Examples 10 to 11 all had high sensitivity, specificity and sensitivity.
[0166] The present application is described in detail above in conjunction with the embodiments, but the present application is not limited to the above embodiments, and various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present application. In addition, the embodiments of the present application and the features in the embodiments can be combined with each other without conflict.
Claims
1. an antibody or antigen-binding fragment thereof that binds to human cytomegalovirus, It is characterized in that It includes a heavy chain variable region and a light chain variable region; the heavy chain variable region includes HCDR1 as shown in SEQ ID NO.9, HCDR2 as shown in SEQ ID NO.10 and HCDR3 as shown in SEQ ID NO.11, and the light chain variable region includes LCDR1 as shown in SEQ ID NO.12, LCDR2 as shown in SEQ ID NO.13 and LCDR3 as shown in SEQ ID NO.
14.
2. The antibody or antigen-binding fragment thereof according to claim 1, It is characterized in that The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
3.
3. The antibody or antigen-binding fragment thereof according to claim 1, It is characterized in that The antibody or antigen-binding fragment thereof is selected from at least one of full-length antibody, Fab, Fab', F(ab')2, Fv, and scFv.
4. The antibody or antigen-binding fragment thereof according to claim 1, It is characterized in that It also includes at least one of a heavy chain constant region and a light chain constant region, wherein the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.6; and / or the amino acid sequence of the light chain constant region is shown in SEQ ID NO.
7.
5. The antibody or antigen-binding fragment thereof according to claim 1, It is characterized in that The antibody or antigen-binding fragment thereof is any one of a human antibody, a humanized antibody and a chimeric antibody.
6. Biomaterials, It is characterized in that The biological material includes any one of B1) to B4); B1) a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1) or the expression cassette described in B2); B4) A recombinant cell containing the nucleic acid molecule described in B1) or the expression cassette described in B2) or the recombinant vector described in B3).
7. Pharmaceutical compositions, It is characterized in that Comprising an effective dose of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, or the biological material according to claim 6.
8. Test kit, It is characterized in that The invention comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5.
9. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 7, or the kit according to claim 8 in the preparation of a product for diagnosis or treatment of human cytomegalovirus.
10. An antibody or antigen-binding fragment thereof that binds to human cytomegalovirus, It is characterized in that It includes a heavy chain variable region and a light chain variable region; the heavy chain variable region includes HCDR1 as shown in SEQ ID NO.15, HCDR2 as shown in SEQ ID NO.16 and HCDR3 as shown in SEQ ID NO.17, and the light chain variable region includes LCDR1 as shown in SEQ ID NO.18, LCDR2 as shown in SEQ ID NO.19 and LCDR3 as shown in SEQ ID NO.
20.
11. The antibody or antigen-binding fragment thereof according to claim 10, It is characterized in that The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.4, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.
5.
12. The antibody or antigen-binding fragment thereof according to claim 10, It is characterized in that The antibody or antigen-binding fragment thereof is selected from at least one of full-length antibody, Fab, Fab', F(ab')2, Fv, and scFv.
13. The antibody or antigen-binding fragment thereof according to claim 10, It is characterized in that It also includes at least one of a heavy chain constant region and a light chain constant region; the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.6; and / or the amino acid sequence of the light chain constant region is shown in SEQ ID NO.
7.
14. The antibody or antigen-binding fragment thereof according to claim 10, It is characterized in that The antibody or antigen-binding fragment thereof is any one of a human antibody, a humanized antibody and a chimeric antibody.
15. Biomaterials, It is characterized in that The biological material includes any one of B1) to B4); B1) a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof according to any one of claims 10 to 14; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1) or the expression cassette described in B2); B4) A recombinant cell containing the nucleic acid molecule described in B1) or the expression cassette described in B2) or the recombinant vector described in B3).
16. Pharmaceutical composition, It is characterized in that Comprising an effective dose of the antibody or antigen-binding fragment thereof according to any one of claims 10 to 14, or the biological material according to claim 15.
17. Test kit, It is characterized in that The invention comprises the antibody or antigen-binding fragment thereof according to any one of claims 10 to 14.
18. Use of the antibody or antigen-binding fragment thereof according to any one of claims 10 to 14, or the pharmaceutical composition according to claim 16, or the kit according to claim 17 in the preparation of a diagnostic product for human cytomegalovirus.
19. A method for detecting human cytomegalovirus in a sample for purposes other than diagnosis or treatment of a disease. It is characterized in that The method comprises contacting the sample with the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 and 10 to 14.
